{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diarrhoea-antibiotic-associated/background-information/risk-factors/","result":{"pageContext":{"chapter":{"id":"7804f825-6a78-5c22-89f7-9ecb4f2ac588","slug":"risk-factors","fullItemName":"Risk factors","depth":2,"htmlHeader":"<!-- begin field ce858244-413b-42f7-a3cd-817194eb3dd2 --><h2>What are the risk factors for Clostridium difficile infection?</h2><!-- end field ce858244-413b-42f7-a3cd-817194eb3dd2 -->","summary":"","htmlStringContent":"<!-- begin item d68127f6-15a4-45be-b13b-37850872c1c1 --><!-- begin field 2cc67169-8ac9-4f2d-a1e3-594504b063c9 --><ul><li><strong>The risk factors for <em>Clostridium difficile </em>infection include: </strong><ul><li>Increased age (more than 65 years old) — UK surveillance data found 80% of reported cases were in this age group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Health Protection Scotland, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">PHE, 2018a</a>].  </li><li>Antibiotic treatment — this allows <em>C. difficile</em> to flourish by suppressing the normal bowel microbiota. Almost all drugs with antibacterial activity have been implicated with antibiotic-associated diarrhoea. Antibiotics that have been frequently associated with <em>C. difficile</em> infection include clindamycin, cephalosporins (especially third and fourth generation), fluoroquinolones, and broad-spectrum penicillins. The risk of <em>C. difficile </em>is also increased with longer duration of antibiotic treatment, multiple antibiotics prescribed concurrently, or multiple courses of antibiotics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Brown et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Deshpande et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Winslow et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">NICE, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Trubiano et al, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Health Protection Scotland, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Ong et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">McDonald et al, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">PHE, 2018a</a>]. </li><li>History of <em>C. difficile </em>infection — recurrence risk is 20% after the first episode and 60% after multiple previous recurrences [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Leffler and Lamont, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Health Protection Scotland, 2017</a>]. </li><li>Exposure to other cases — <em>C. difficile </em>infection can occur in outbreaks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Sams and Kennedy-Malone, 2017</a>]. </li><li>Current use of a proton pump inhibitor or other acid-suppressive drugs (such as H<sub>2</sub>-receptor antagonists) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Tleyjeh et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Tariq et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Trifan et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Cao et al, 2018</a>].</li><li>Underlying morbidity such as abdominal surgery, chronic renal disease, inflammatory bowel disease, immunosuppression (such as solid organ or haematopoietic stem cell transplant recipients, people with HIV infection, people undergoing cancer chemotherapy) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Health Protection Scotland, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">McDonald et al, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Hassoun, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">PHE, 2018a</a>].  </li><li>Prolonged hospitalization or residence in a nursing home [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Health Protection Scotland, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">Hassoun, 2018</a>].</li></ul></li></ul><!-- end field 2cc67169-8ac9-4f2d-a1e3-594504b063c9 --><!-- end item d68127f6-15a4-45be-b13b-37850872c1c1 -->","topic":{"id":"e3d5d597-cb8d-5009-95be-96d5f61f622c","topicId":"60505e59-3d44-4100-ba77-670b2dda81a3","topicName":"Diarrhoea - antibiotic associated","slug":"diarrhoea-antibiotic-associated","lastRevised":"Last revised in November 2020","chapters":[{"id":"ff00d31e-fff0-5539-893c-63eaae28aa91","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d4f02cb1-a605-5763-85b8-7e30efe0b52d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b4be21a4-fea2-52ee-99b9-6ad9b7f42b37","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"14b5fd2c-0a9a-58b3-af3b-54e8f6c587a3","slug":"changes","fullItemName":"Changes"},{"id":"86cd74d6-6f35-5de4-9031-55397958409b","slug":"update","fullItemName":"Update"}]},{"id":"d9b8d789-d6e6-5a0f-80ef-2853843c67b6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"93a9787b-a3ca-5bd2-9dd1-e7bd5ebd7e61","slug":"goals","fullItemName":"Goals"},{"id":"712c6134-ba14-5e2a-987b-8d3c06033ee0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"04b62294-302f-5852-90f5-60c1f9593a96","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"98b4954c-4b96-5b7a-9888-99cfd0b2ce3d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7f04cf05-c2de-5fb3-9f58-b7e32b7a8604","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d849aa0f-051e-5e61-8d05-6da99fdc60e0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"146be3ba-ef2c-5d7c-a6be-75d743b6cbdb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3deeffef-b60e-557b-a9ce-2ca055de0653","slug":"definition","fullItemName":"Definition"},{"id":"788d8348-35a0-5147-b765-a90a068257b9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7804f825-6a78-5c22-89f7-9ecb4f2ac588","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4d2b177e-1c5d-5783-b256-b0b7173e4660","slug":"complications","fullItemName":"Complications"},{"id":"0d3b3c20-ff70-5653-9cb1-750667c15098","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"db6311c9-b63f-5037-89f3-fe2ed41761c7","fullItemName":"Management","slug":"management","subChapters":[{"id":"1ddecd55-2bf4-53db-8594-8c1489126404","slug":"diarrhoea-antibiotic-associated","fullItemName":"Scenario: Diarrhoea - antibiotic associated"}]},{"id":"e0650ec6-ca9b-5cf0-9761-2ffe00571666","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4f209e3e-56a5-5f47-859e-8b6f0b9b9fe9","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"1a19af07-ea9e-59ac-8ce6-508d4d01e536","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ecd4dd69-cf4c-507f-9659-b23f2a5b3272","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b0079d2b-b8c1-59e3-a1c1-f6f2c83a07c5","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"919502d7-1740-58a4-8ea5-2feeb47d6e28","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d1844305-0beb-50de-a2de-fbea6a58b880","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"766c971f-c448-56d3-a9d4-2ffded846f90","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7d18a1e0-eeb3-5b2f-bd26-e9f231d83c40","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"99309640-cab2-57c4-8bd0-2c05065abd69","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"146be3ba-ef2c-5d7c-a6be-75d743b6cbdb","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}